Enveric Biosciences annual r&d spending
2016
2020
2021
2022
2023
2024
2025
Enveric Biosciences R&D Spending Growth & History (ENVB)
Enveric Biosciences's r&d spending was $2.8M for fiscal 2025.
View full Enveric Biosciences company overviewEnveric Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.8M | −$60,255 | −2.12% |
| 2024 | 2024-12-31 | $2.8M | −$4.4M | −60.82% |
| 2023 | 2023-12-31 | $7.3M | −$775,336 | −9.66% |
| 2022 | 2022-12-31 | $8.0M | $3.2M | +67.64% |
| 2021 | 2021-12-31 | $4.8M | $4.6M | +2650.88% |
| 2020 | 2020-12-31 | $174,083 | — | — |
| 2016 | 2016-12-31 | $55,104 | — | — |
Enveric Biosciences quarterly r&d spending
Q2.10
Q2.11
Q1.17
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | $95,086 | +7.55% |
| Q1 2026 | 2026-03-31 | $345,969 | −$400,402 | −53.65% |
| Q4 2025 | 2025-12-31 | $372,178 | −$595,221 | −61.53% |
| Q3 2025 | 2025-09-30 | $402,417 | −$400,300 | −49.87% |
| Q2 2025 | 2025-06-30 | $1.3M | $695,050 | +123.02% |
| Q1 2025 | 2025-03-31 | $746,371 | $240,216 | +47.46% |
| Q4 2024 | 2024-12-31 | $967,399 | −$782,202 | −44.71% |
| Q3 2024 | 2024-09-30 | $802,717 | −$478,738 | −37.36% |
| Q2 2024 | 2024-06-30 | $565,001 | −$1.8M | −76.41% |
| Q1 2024 | 2024-03-31 | $506,155 | −$1.3M | −72.28% |
| Q4 2023 | 2023-12-31 | $1.7M | −$143,751 | −7.59% |
| Q3 2023 | 2023-09-30 | $1.3M | −$774,201 | −37.66% |
| Q2 2023 | 2023-06-30 | $2.4M | $275,538 | +13.00% |
| Q1 2023 | 2023-03-31 | $1.8M | −$132,922 | −6.79% |
| Q4 2022 | 2022-12-31 | $1.9M | −$638,321 | −25.21% |
| Q3 2022 | 2022-09-30 | $2.1M | $836,317 | +68.59% |
| Q2 2022 | 2022-06-30 | $2.1M | $1.2M | +140.96% |
| Q1 2022 | 2022-03-31 | $2.0M | $1.8M | +1140.07% |
| Q4 2021 | 2021-12-31 | $2.5M | — | — |
| Q3 2021 | 2021-09-30 | $1.2M | $1.2M | +1826.23% |
| Q2 2021 | 2021-06-30 | $879,843 | $828,886 | +1626.64% |
| Q1 2021 | 2021-03-31 | $157,952 | — | — |
| Q3 2020 | 2020-09-30 | $63,302 | — | — |
| Q2 2020 | 2020-06-30 | $50,957 | — | — |
| Q1 2017 | 2017-03-31 | $0 | — | — |
| Q2 2011 | 2011-06-30 | $0 | $0 | — |
| Q2 2010 | 2010-06-30 | $0 | — | — |
Enveric Biosciences r&d spending trends
Over the last five fiscal years, Enveric Biosciences's r&d spending increased from $174,083 to $2.8M, a change of $2.6M. The latest reported quarter, Q2 2026, shows $1.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Enveric Biosciences source filings ↗